The following financial analysts monitor the market environment and the performance of Aurubis AG and make investment recommendations in accordance with their analyses and reports on Aurubis shares. The following list is not necessarily exhaustive.
Buy (overweight/outperform/add): The price of the analyzed share is expected to rise over the next 12 months.
Hold (equal-weight/neutral): The price of the analyzed share is expected to remain mostly flat over the next 12 months.
Sell (underweight/underperform/reduce): The price of the analyzed share is expected to fall over the next 12 months.
|Company||Analyst||Recommendation||Target price in €|
|Baader Bank||Christian Obst||Buy||80|
|Bank of America / Merrill Lynch||Kevin Kerdoudi||Underperform||65|
|Deutsche Bank||Bastian Synagowitz||Hold||67|
|DZ Bank AG||Dirk Schlamp||Buy||83|
|Exane BNP Paribas||Jatinder Goel||Underperform||63|
|Hauck & Aufhaeuser||Henning Breiter||Hold||51|
|Independent Research||Sven Diermeier||Hold||71|
|Kepler Cheuvreux||Rochus Brauneiser||Reduce||60|
|M.M. Warburg||Eggert Kuls||Hold||71.3|
* Coverage currently suspended due to a change in analyst.
** Coverage terminated at the end of 2020.
Data as of April 16, 2021
Note: The analyst estimates presented are not based on research conducted by Aurubis AG, but on the assessments, reports, recommendations, and analyses of the listed equity research analysts. The presentation of this information as a service for our shareholders does not mean that Aurubis AG adopts, supports, or confirms the analysts' recommendations. None of the data and information provided on this website constitutes an offer to buy, sell, or otherwise trade in securities. In particular, the information does not contain any recommendation for an investment strategy. Aurubis AG accepts no liability whatsoever for the selection, completeness, or correctness of the analysts' assessments presented here. Aurubis AG accepts no liability for damages incurred by third parties as a result of information on this website.